Loading...
Recent trials cast doubt on the assumption that intensive glucose-lowering treatment in patients with type 2 diabetes lowers short- or long-term mortality and adverse cardiovascular (CV) events. In this meta-analysis of 13 randomized controlled trials, researchers addressed outcomes with intensive glucose-lowering.
Overall, 35,000 patients (mean age, 62) received either intensive or standard glucose-lowering treatment. After a mean follow-up of 5 years, intensive glucose lowering was not associated with lower risks for all-cause mortality and CV death; in fact, these adverse outcomes were slightly — although nonsignificantly — more common with intensive treatment (risk ratios, 1.04 and 1.11, respectively). Patients randomized to intensive gl…